Changes of APRI score in HBeAg-negative treatment-naive chronic hepatitis B patients receiving 3 year entecavir therapy
10.3760/cma.j.issn.1003-9279.2019.03.017
- VernacularTitle: HBeAg阴性初治慢乙肝患者恩替卡韦3年抗病毒治疗APRI评分动态变化研究
- Author:
Ruyu LIU
1
;
Lu ZHANG
;
Yao LU
;
Ge SHEN
;
Shuling WU
;
Mi CHANG
;
Hongxiao HAO
;
Yuanjiao GAO
;
Minghui LI
;
Yao XIE
Author Information
1. Second Division of Liver Center, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
- Publication Type:Journal Article
- Keywords:
Chronic hepatitis B;
Liver fibrosis;
Entecavir;
APRI
- From:
Chinese Journal of Experimental and Clinical Virology
2019;33(3):309-313
- CountryChina
- Language:Chinese
-
Abstract:
Objective:We aimed to evaluate changes towards liver fibrosis during entecavir(ETV)treatment by non-invasive fibrosis markers in chronic hepatitis B (CHB) patients who need antiviral therapy.
Methods:Totally 303 HBeAg negative treatment-naive CHB patients were enrolled and liver biopsy was performed before starting antiviral therapy in this study. Totally 196 patients who need antiviral therapy were treated with ETV for at least 3 years. A clinical and virological evaluation was performed at baseline and again after 1, 2 and 3 years during ETV treatment. AST-to-platelet ratio index (APRI) was used to assess dynamic changes of liver fibrosis in HBeAg negative CHB patients after 1, 2, 3 years of ETV treatment.
Results:All enrolled patients experienced liver biopsy at baseline. According to Metavir fibrosis stages, F1, F2, F3 and F4 patients were 107, 125, 54 and 17, respectively. The APRI score enabled the correct identification of patients with severe fibrosis (METAVIR F3-F4). The APRI values significantly decreased in F2 and F3 patients after 1 year ETV therapy (P<0.01). But for F4 patients, APRI values decreased significantly at year 3 (P<0.05).
Conclusions:APRI values decreased significantly during ETV treatment in HBeAg-negative CHB patients indicating that these noninvasive fibrosis tests might be useful for monitoring improvement of liver fibrosis and assessing treatment efficacy during long-term ETV treatment.
